摘要
目的:比较研究不同产地雄黄及其炮制品中主成分As2S2及可溶性砷盐As2O3的含量差异。方法:采用2010年版《中国药典》雄黄项下的滴定法测定不同产地雄黄及其炮制品中As2S2的含量,采用AFS-230E型原子荧光光度计检测上述样品中可溶性砷盐As2O3含量。结果:不同产地的雄黄及其炮制品中As2S2,As2O3含量存在显著差异。雄黄炮制后,炮制品中As2S2含量均提高,As2O3含量均明显降低。除吉林和江苏2个产地的的雄黄及其炮制品中As2S2含量<90.0%,其余样品均符合药典规定;且雄黄炮制品中As2O3含量均能控制在1.7 mg.g-1以下。结论:研究结果可为指导雄黄临床合理用药提供参考依据。
Objective： To study the content difference of the principal component （As2S2 ） and the soluble arsenic salt （As2O3 ） in realgar and it processed products from different origins. Method： As2S2 content was determined by titration based on the analysis method of realgar recorded in Chinese Pharmacopoeia （2010 edition）, and As2O3 content was detected using AFS-230E Atomic fluorescence speetrophotometer. Result： The contents of As2S2 and As2O3 were significantly different in realgar and its processed products from different origins. After processing, A%S2 content in the processed products was obviously increased, while A%03 content was significantly reduced. Except that As2S2 content in realgar and its processed products from Jilin province and Jiangsu province was less than 90. 0% , the rest of the samples can meet the pharmacopoeia requirements, and As2O3 content in all of the processed products can be controlled below 1.7 mg ·g-1. Conclusion： This findings can provide a reference for guiding rational clinical applications of realgar.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第2期49-52,共4页
Chinese Journal of Experimental Traditional Medical Formulae
基金
国家"重大新药创制"科技重大专项(2009ZX09301-005)
国家科技部科研院所基础研究专项基金(2002DEB20067)
国家"十一五"科技支撑计划项目(2006BAI55B02-03)
